Clinical trial

RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

NCT00101972

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-12-01

PhasePHASE1

Study timeline

Study start (unknown)2004-12-01Date precision: month

Registry last updated2022-02-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Cancerunresolved

Interventions

monoclonal antibody RAV12BIOLOGICAL

Sponsors & collaborators

MacroGenicslead sponsor

Mapped research locations

PhiladelphiaPennsylvania, United States1 MiamiFlorida, United States1 NashvilleTennessee, United States1 Washington D.C.District of Columbia, United States1 Santa MonicaCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00101972 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.